Dean David Perlmutter, MD, is aligning resources at the School of Medicine to focus on ­personalized, precision ­medicine: managing health ­instead of disease, providing the right ­treatment for the right patient, and developing drugs and other ­therapies faster and at lower cost.

Pursuing a precision paradigm

Why move from current standards of patient care to a more personalized approach to treatment? Experts at the School of Medicine describe today’s medical landscape as they plan for the care — and cures — of the future.

Of the top-grossing domestic movies of 2017 to date, three of the Top 5 feature superheroes: ­Wonder ­Woman; Guardians of the Galaxy, Vol. 2; and ­Spider-Man: Homecoming. Similarly, in 2016, five of the Top 10 ­movies focus on adventure and heroes, including ­Captain ­America: Civil War and Batman v Superman: Dawn of Justice. Studying the genre, examples emerge at the top of movie lists year after year. In these films, the “heroes” venture out and engage in great and noble deeds against incredible odds on ­behalf of a group, ­population or civilization.

The battle between good and evil is a consistent theme in art and considered a timeless and universal element of the ­human condition — not unlike the age-old battle between health and disease.

Cancer, Alzheimer’s, multiple sclerosis, inflammatory ­bowel disease, diabetes, heart disease and more are formidable foes. Yet in their quest to conquer these debilitating, sometimes life-threatening adversaries and save lives, the ­Washington ­University Medical Center and its bold team of ­physicians and research scientists are starting to wield new, more ­precise weaponry.

As these bright, committed men and women stand on the threshold of a revolution in medicine, they are primed to ­confront new obstacles and venture down new pathways in their pursuit of precision therapies designed for individual patients.

Dean David Perlmutter, MD, promotes a revolutionary ­approach to health care, positioning the medical school to make an even bigger difference in patients’ lives. (Photo: James Byard)
Dean David Perlmutter, MD, is promoting a revolutionary ­approach to health care, positioning the medical school to make an even bigger difference in patients’ lives. (Photo: James Byard)

The vision: imagining what science can do

David Perlmutter, MD, might question the label “hero,” yet he focuses his highly ­developed skills on behalf of society. Among his proficiencies is transformational leadership. As executive vice chancellor for medical affairs and dean of the School of Medicine, he directs a vast organization: hundreds of ­brilliant physicians, physician-scientists and research ­scientists; the No. 1 program in the country training MD/PhDs (the ­physician-scientists of tomorrow); the No. 1 Alzheimer’s disease research center; the No. 3 cancer center; and leading departments and centers in genomics, immunology, ­microbiology, pediatrics and more.

Perlmutter also possesses keen ­vision. He sees the future of medicine right now: a “precision paradigm,” supporting the personalized treatment of patients, rather than the ­current standards of care that guide treating all patients with the same condition. By leveraging the medical school’s ­incredible strengths today, Perlmutter is ­positioning his team to make an even greater impact on human health tomorrow.

The landscape en route to making this revolutionary shift is also being made over. The Washington University ­Medical Center — Barnes-Jewish and St. Louis Children’s hospitals, BJC HealthCare and the Washington University School of ­Medicine — is in the middle of a multiphase, long-term ­campus renewal project. The objective: to foster more ­collaborative medical discovery and improve patient care.

From his office on the 12th floor of the new Mid Campus Center, Perlmutter is situated at the heart of this renewal. Underlying his vision and these infrastructure modifications is a major transformation in the academic, medical profession in general: a big change in the way physicians and research scientists view patients.

For a very long time, the medical profession has known that patients have different characteristics impacting their disease, but because of the state of knowledge, clinicians and research scientists had to lump them into disease groups. Perspectives started to shift once the sequencing of the human genome was completed in 2003. Researchers could then begin to see the genetic variations in patients and consider their unique ­susceptibilities to disease.

Perlmutter shares an example from his time as a clinician to further explain. A pediatric gastroenterologist, he has many years’ experience taking care of children with inflammatory bowel disease (IBD), which, according to the textbooks, can be broken down into two disease types: ulcerative colitis and Crohn’s disease. Yet Perlmutter knew early in his career that not all of his patients diagnosed with having ulcerative colitis responded the same way to the standard treatment for the condition, and the same was true of his patients with Crohn’s disease. Fast forward to today, and through genetic sequencing and analysis, researchers now know that more than 220 genetic variants are associated with IBD.

“We were practicing medicine for children with IBD — and we still are today — based on a two-disease view, and ­treatments are designed for this two-disease view,” ­Perlmutter says. “But the truth is, one person’s disease is different from the next person’s.” This treatment model — not knowing or considering the different mechanisms occurring in ­individual patients — is behind the shortcomings of current IBD therapies as well as treatment for other diseases.

Still, Perlmutter emphasizes, it isn’t enough just to note these genetic differences — these sequence variants — among patients.

“Our position now is to figure out how to capitalize on these differences, not only to understand the disease better, but to develop better diagnostics and better therapies that lead to better patient outcomes,” Perlmutter says. “Further, by ­investigating variants, we are almost always learning ­something new about the function of the affected gene, and this means advancing new knowledge about basic biological mechanisms of the living organism. And that’s very motivating.”

Another very important outcome of the personalized medicine paradigm, Perlmutter says, is that clinical trials will happen more quickly, will be more likely to give a definitive answer, and will be much less expensive because subjects of the trials will be genomically defined. “With a better evidence base and the ability to target expensive therapies to specific patient subgroups and, in some cases, avoid the need for any ­interventions, we will put ourselves in a position to reduce the cost of health care in a transformational way,” he says.

Perlmutter is promoting personalized, precision medicine because it’s a “powerful and revolutionary idea.” He says that it’s an enlightened view as well — and why he believes Washington University is so well-positioned to lead this ­transformation in medicine.

“The School of Medicine is one of several places in the world where the physician-scientist has been a primary focus, and in many ways this shift is the next evolution of the ­physician-scientist,” Perlmutter says. “This shift demonstrates the true value of understanding disease and ­taking care of disease — and being able to imagine what science can do to ­improve on that. It’s the validation of why we want to have people who understand both clinical medicine and very ­sophisticated basic science.”

Herbert W. “Skip” Virgin IV, MD, PhD, is the ­Edward Mallinckrodt Professor and head of the ­Department of Pathology and ­Immunology. (Photo: Robert Boston)
Herbert W. “Skip” Virgin IV, MD, PhD, is the ­Edward Mallinckrodt Professor and head of the ­Department of Pathology and ­Immunology. (Photo: Robert Boston)

The landscape: determining genes, environmental triggers, pathways

By design, scientists who fit that ­archetype blanket the School of ­Medicine. Some of these ­dreamers, ­seekers, ­hunters, ­explorers and ­investigators lead departments, ­institutes, ­centers and labs; some work at the bench, ­creating model systems and ­searching for ­genetic variants, mutations, signals and pathways; and still others delve into ­environmental ­influences, bacteria and viruses — ­pursuing clues to deciphering the causes of disease while decoding ­possible novel sites for targeted therapies.

This article can highlight only a very few of the ­brilliant minds who, through their dogged determination, are ­hastening the school’s evolution toward personalized, ­precision ­medicine by focusing on managing health instead of disease, providing the right treatment for the right patient, and developing drugs and other therapies faster and at lower cost.

One such investigator is Herbert W. “Skip” Virgin IV, MD, PhD, the ­Edward Mallinckrodt Professor and head of the ­Department of Pathology and ­Immunology.

Virgin explains that you can ­personalize care for ­people only if you can diagnose what about them needs a ­specific therapy, and that’s where his ­department comes in. On the pathology side, for example, if a person has cancer, it isn’t always true that a certain ­chemotherapy will work or work well. So Virgin’s ­department ­deep-sequences cancer genes in tumors and then reports back to the ­oncologist. Then the oncologist can know what therapeutic choices might be most ­beneficial for a particular patient.

On the immunology side, using IBD as an ­example (as Perlmutter referenced), Virgin explains that in the last 10 years, researchers ­discovered a strong genetic component for both the susceptibility and the ­severity of ­ulcerative colitis and Crohn’s ­disease. One ­question researchers have ­subsequently asked is, How much of the risk, say, for Crohn’s disease, is in the genes? The generally accepted answer is less than 20 percent, ­meaning that 80 percent of the risk is due to something else. And researchers now think that ­“something else” is environment: where we live; what our ­current ­exposures are; what our exposures were early in life, ­including to antibiotics, which could change our gut bacteria and permanently imprint our ­immune ­system; and what our microbiome — the ­bacteria, ­viruses, fungi and worms that live in and on us in ­enormous quantities — is like.

In Virgin’s lab, researchers ­specialize in a part of the ­microbiome that’s called the virome, and they have been among the leaders ­in relating viruses to ­susceptibility in ­inflammatory bowel disease, AIDS, risk for HIV acquisition, diabetes and more.

In a recent diabetes study, for example, Virgin ­discovered viruses that conferred risk for type I ­diabetes as well as a virus that looked as if it conferred ­protection against the disease. “It’s a virus that could be good, and it just makes sense,” ­Virgin says. “We’ve got ­bacteria that are good for us: They digest our food; they make vitamins that are very important for our body. And then there are pathogenic bacteria. Viruses are the same. We don’t want HIV, hepatitis C, influenza. But there’s a huge number of nonpathogenic viruses, which probably ­confer benefit to the host.”

In Virgin’s lab, they’re also researching a certain set of genes in a process called autophagy, which is an intracellular degradation system that can also be a major determinant of disease ­susceptibility and outcomes. They’re studying the mechanism and then developing drugs — compounds to correct defects or take advantage of what they’ve learned about this pathway to treat disease.

Again with IBD, researchers are going after this specific ­pathway therapeutically because they have discovered that one of the genes for Crohn’s is an autophagy gene. Now, can they make a drug that targets autophagy and treats Crohn’s disease? “That’s what we’re trying to do, and we’ll know when we’ve done it,” Virgin says.

Like Perlmutter, Virgin imagines this as the future of all ­advances in medicine. “We study genes and figure out why a variation is related to a disease; we study environmental triggers; and then we do our very best to take apart a ­specific pathway — a gene or a pathway — that will lead to the ­development of therapeutics,” he says.

Jeff Milbrandt, MD, PhD, is the James S. McDonnell ­Professor of Genetics and head of the James S. McDonnell ­Department of Genetics. (Photo: Mark Katzman)
Jeff Milbrandt, MD, PhD, is the James S. McDonnell ­Professor of Genetics and head of the James S. McDonnell ­Department of Genetics. (Photo: Mark Katzman)

The dream: fixing mutations and altering pathways

Jeff Milbrandt, MD, PhD, is a dreamer. One of the medical school leaders who first recognized the need for using DNA ­sequencing in the clinical arena, he now heads the James S. McDonnell ­Department of Genetics. Milbrandt, the James S. McDonnell ­Professor of Genetics, says that we’re living in the “fanciful era” now — an era of genome editing, in which ­researchers have the power to alter genes. Further, they’re able to generate induced pluripotent stem cells (iPSC), taking skin cells or cells from blood or urine and transforming them into stem cells. These stem cells can then be converted into almost any cell in the body, providing a system for studying how ­specific mutations lead to cell malfunction and cause disease.

To do this, scientists use CRISPR technology — a powerful editing tool that allows them to easily alter DNA ­sequences and modify gene function. In addition to editing cell lines and generating iPSCs, they can create model systems to explore and screen for thousands of drugs to see if any ­reverse a specified mutation. This is all happening now.

“In the next five years,” Milbrandt says, “we’re going to go from cataloguing mutations — and saying, ‘This mutation is ­causing this particular problem’ — to ­fixing the mutation using CRISPR. Then we’re going to inject these CRISPR components, in the form of a virus, into your body and basically, magically, fix the mutation.”

Milbrandt says that although some ethical concerns ­remain, progress is ­inevitable. He says he can ­visualize ­incredible advancements on the ­horizon — a day when someone with muscular dystrophy will walk, or when someone with retinitis pigmentosa will see. “This is not futuristic stuff anymore,” he says. “It will soon be reality.”

To position the medical school at the leading edge of this work, Milbrandt and others have created the Genome ­Engineering and iPSC Center to assist other investigators in using CRISPR genome engineering for their studies. (To learn more about centers playing pivotal roles in the medical school’s ­efforts in precision medicine, see related content: “Building the foundation for discovery.”)

In his own work, Milbrandt studies peripheral ­neuropathy, a condition that develops as a result of damage to the ­peripheral nervous system. Symptoms range from muscle ­tingling and weakness to pain and paralysis. This condition can be inherited or induced by diabetes or chemotherapy ­treatment for cancer. ­Chemotherapy is helping save more and more lives, yet at the same time, more folks are affected by the painful ­neurological side effects of their treatment.

Using the latest technologies, ­Milbrandt and ­collaborator Aaron ­DiAntonio, MD, PhD, the Alan A. and Edith L. ­Profe­ssor of ­Developmental ­Biology, are working to understand the exact pathways that lead to the root cause of neuropathy: axonal degeneration. They have found the central executioner of this ­destructive ­process and have good leads on small-­molecule drugs that might work in neuropathy, but they are also testing whether gene therapy with viruses can fix the degeneration directly.

“As we delve more deeply into the fundamental ­pathways that are being altered by these diseases, we start to see ­commonalities,” Milbrandt says. “For instance, the axonal degeneration that happens in neuropathy also happens in Alzheimer’s, Parkinson’s, MS and other diseases. By dreaming big and discovering a way to block that sort of degeneration, we could possibly impact all these disorders.”

Tim Eberlein is director of the Alvin J. Siteman Cancer Center. The Bixby Professor of Surgery, he also chairs the surgery department, serves as the Spencer T. and Ann W. Olin Distinguished Professor at the School of Medicine and as surgeon-in-chief at Barnes-Jewish Hospital. (Photo: James Byard)
Tim Eberlein is director of the Alvin J. Siteman Cancer Center. The Bixby Professor of Surgery, he also chairs the surgery department, serves as the Spencer T. and Ann W. Olin Distinguished Professor at the School of Medicine and as surgeon-in-chief at Barnes-Jewish Hospital. (Photo: James Byard)

A model: personalizing cancer care

Perhaps no area at the university is as far ahead in the progression toward personalized, precision ­medicine as the Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

In the last 20 years, mortality from cancer — the No. 2 leading cause of death today in the United States — has decreased by 25 percent. And, according to Tim Eberlein, MD, director of Siteman Cancer Center, that drop in ­mortality is ­going to ­accelerate, because researchers are “now at the ­threshold of ­being able to control the disease instead of the disease ­controlling us.”

With that goal in sight, Siteman has established very large, robust programs in leukemia, lymphoma, myeloma, breast cancer, lung cancer, brain cancer and more. And it has outlined four major strategic initiatives in collaboration with other departments to advance care: genomics, immunology/immune ­therapies, technology and imaging, and prevention.

Regarding the first initiative, researchers at ­Washington University have made a massive ­effort since the sequencing of the human genome to identify genomic information associated with cancers. Eberlein estimates that nearly 99 percent of the mutations associated with human cancer have been identified. Siteman Cancer Center and the Elizabeth H. and James S. McDonnell III Genome Institute led this global effort. (See ­related story above, “Undaunted explorer” to learn more about the work of Timothy Ley, MD, who inspired and collaboratively led the team that sequenced the first cancer genome in 2008, and the challenges he has faced and insights he has gleaned in treating patients with acute myeloid leukemia ever since.)

“We realize now that cancer is thousands of ­different ­diseases,” says Eberlein, who is also the Bixby Professor of Surgery and head of the Department of Surgery at the School of ­Medicine. “So Patient A’s breast cancer, for example, may be very different from Patient B’s breast cancer, even if the two cancers look the same under a microscope, are the same size or are in the same breast. These differences are based on ­molecular and genetic markers that cause the cancer to ­behave in different ways.”

Eberlein says the question now is, How do scientists ­apply that knowledge to diagnose and treat the next individual ­patient who walks through the door?

Siteman’s second initiative centers on immunology and targeted immune therapy. For years, researchers — ­including Robert Schreiber, PhD, the Andrew M. and Jane M. Bursky Distinguished Professor of Pathology and Immunology and director of the Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs — have been studying how to turn on a ­patient’s ­immune system to make it recognize and ­destroy cancer cells, as well as how to control the process so it doesn’t also destroy normal cells and normal function.

“Genomic analysis on breast cancer patients’ tumors, for ­example, has shown there are different mutations that are signatures to individual patients,” Eberlein says. ­Researchers collect these unique mutations, create a vaccine that ­targets them and then administer it to individual patients to stimulate their immune system to recognize the specific mutations. “This is more precise in destroying diseased cells than ­radiation or even surgery, and there is less damage to healthy tissue,” Eberlein says.

Today, researchers are conducting such trials in breast and brain cancers, and they’re in various stages of development in head and neck, lung, lymphoma, melanoma, pancreas, prostate and retinal cancers. “And we don’t do this research in silos,” Eberlein says. “We gather experts in these various areas and discuss developments as a group: ‘What did you learn in studying brain cancer, and how could we apply that in breast cancer, and vice versa?’ Cross-fertilization is a strength of ­Siteman’s, and it helps accelerate how fast we can do these kinds of studies.”

The third initiative encompasses technology and ­imaging. For example, Siteman has the ability to detect cancer cells through photo-acoustic imaging. And it can insert an ­individual gene into a normal cell to study its impact, if any, on cell growth and division. Siteman also has invested ­heavily in understanding the molecular mechanisms of ­various pathways in cancer.

Again, how does exploring pathways promote progress ­toward precision medicine?

Eberlein explains that “as we study these pathways, we’re beginning to realize that some of them drive the growth of cancer cells. So we’re beginning to develop drugs and interventions that interrupt these ­pathways.”

To further explain, Eberlein hypothesizes two patients, Patient A and Patient B, who have the same leukemia. If each patient’s cancer is promoted by a different pathway, each cancer will respond differently to the same drug therapy, if at all.

There’s another benefit of discovering these pathways. “In lung cancer, for example, we identified a mutation that also ­occurs in a minority of colon cancers,” he says. “We have a drug for this subset of colon cancers that we never would have thought to use for lung cancer before we discovered this similarity.”

The discovery is another example of how understanding the biology of the disease and the molecular and genetic ­information of the pathways can inform physicians on how to treat certain patients in a very personalized way.

“These developments aren’t going to happen in 50 years,” Eberlein says. “They’re happening right now.”

One of the most ambitious developments in Siteman’s plan to save lives and help communities is conceivably through its fourth initiative: prevention.

The BJC HealthCare organization has collaborative relationships with eight other health-care systems — not hospitals, but entire systems that together cover much of ­Missouri and the southern half of Illinois. The region includes four of the top six counties in the country for cancer deaths. And Siteman, recognized as a Comprehensive Cancer Center by the National Cancer Institute since 2005, is proposing to these systems a collaborative and mutually beneficial arrangement: Siteman would provide effective, evidence-based cancer prevention programs and help oversee them in exchange for access to their patients’ genomic and clinical information. The goal is twofold: advise the other systems on how to care for their patients and build a large, relational database at Siteman. Such a database would help researchers develop algorithms for managing different populations and individuals who have breast cancer, lung cancer, prostate cancer and more.

Eberlein clarifies how this database would help ­personalize treatment. In early breast cancer, for example, stage one/stage two breast cancer, the vast majority of female patients are treated with lumpectomy and radiation therapy, and some have a mastectomy. After these treatments, 80 percent of women with early breast cancer are cured of their disease. Twenty percent, however, have a risk of recurrence.

“Until very recently, if their tumors were bigger than a centimeter, we would treat almost 100 percent of these ­women with multidrug-regimen chemotherapy,” Eberlein says. “But if I had a massive database, I could compare, say, Mrs. Smith’s genetic signatures ­computationally to those of all the other women in the database to see if she had a match for recurrence. If she didn’t, we could provide her with statistical validation and say, ‘You won’t need multidrug-regimen ­chemotherapy.’ If she did have a match for recurrence, we might have to say to her, ‘Mrs. Smith, you match the type of woman who has a high risk of having ­recurrence, so we ­recommend aggressive ­chemotherapy.’”

Although it’s going to take time to work through all the ­various mutations and pathways in all the types of cancer, Eberlein is excited about what’s happening ­already. “One of the first major impacts of precision ­medicine is that it’s going to show us which patients we should not be treating aggressively,” he says, which will lead to a ­reduction both in ­unnecessary treatment and in costs of health care.

David Holtzman, MD, is the ­Andrew B. and Gretchen P. Jones ­Professor of Neurology, the ­Charlotte and Paul ­Hagemann ­Professor of Neurology, head of the Department of Neurology at the medical school, and neurologist-in-chief at Barnes-Jewish Hospital. (Photo: James Byard)
David Holtzman, MD, is the ­Andrew B. and Gretchen P. Jones ­Professor of Neurology, the ­Charlotte and Paul ­Hagemann ­Professor of Neurology, head of the Department of Neurology at the medical school, and neurologist-in-chief at Barnes-Jewish Hospital. (Photo: James Byard)

The struggle: advancing Alzheimer’s treatment

Another major concern for physician-­scientists is the aging population. The ­average lifespan in the U.S. for a male in 1912 was 51.5 years, whereas in 2012 it was 76.4. For women, the ­increase jumped from 55.9 years to 81.2. We’re ­living longer because we’re surviving cancer, heart disease and other disorders. That’s the good news. The bad news, ­however, is that with an ­increase in ­longevity has come an increase in the ­diseases that ­occur more commonly with age — the ­diseases of the brain — which currently have no great treatments.

Overseeing the department charged with untangling the mysteries of ­neurological ­disorders, including neurodegenerative ­diseases, is David Holtzman, MD, the ­Andrew B. and Gretchen P. Jones ­Professor of Neurology, the ­Charlotte and Paul ­Hagemann ­Professor of Neurology, head of the Department of Neurology at the medical school, and neurologist-in-chief at Barnes-Jewish Hospital. Under his direction is a deep bench of resolute ­researchers working on Alzheimer’s, ­frontotemporal dementia, Parkinson’s, ALS, MS, stroke,­ ­subarachnoid ­hemorrhage and more.

The most common neurodegenerative disease is Alzheimer’s disease, in which both age and genetics play a role. In the neurology department’s Charles F. and Joanne Knight Alzheimer’s Disease Research Center, led by John Morris, MD, the ­Harvey A. and Dorismae Friedman ­Distinguished Professor of Neurology, researchers have determined a number of genetic markers that are risk factors or causative for certain forms of the disease. In addition, in studies of early-onset Alzheimer’s disease, there is a huge research effort in the Dominantly Inherited Alzheimer Network (DIAN) and treatment unit, led by Randall Bateman, MD, the Charles F. and Joanne Knight Distinguished Professor of Neurology. These studies are determining the ­biomarkers and time course of the disease, both before and after the onset of symptoms, as well as testing novel treatments.

“In terms of personalized medicine for early onset, ­individuals are being identified and put in novel clinical ­trials based on family history and specific genetic ­information,” Holtzman says. And for late-onset Alzheimer’s, the most ­common form, Holtzman says the center is identifying people before they’re symptomatic, trying to determine whether ­researchers can predict the onset of symptoms. Some individuals are in clinical trials based on their biomarkers.

“Many individuals in our various clinical research studies are having their genome sequenced completely by ­researchers such as Carlos Cruchaga, PhD, associate professor of ­psychiatry,” Holtzman says. “And that’s providing important information about new genetic factors that lead to the disease, as well as ­identifying new targets for treatment.”
Discussing innovations, Holtzman says that researchers are making advances in better diagnostics that are not as expensive as PET scanning or as invasive as spinal tap. “It needs further development,” Holtzman says, “but there’s a blood test that may enable screening of people for whether or not they’re ­developing the pathology of Alzheimer’s.”

The blood-based screening test, discovered in Bateman’s lab, aims to detect certain forms of amyloid beta, which ­collects in brain amyloid plaques, that are thought to contribute to Alzheimer’s disease and its progression in people before they become symptomatic.

Regarding new therapies, one treatment, developed in Holtzman’s lab a few years ago, is now in Phase II clinical trials. It’s an antibody to tau, which in some people collects into toxic ­tangles that damage brain cells and contribute to neurodegenerative diseases. (See related content, “A promising future,” to learn more about doctoral students contributing to such ­discoveries in Holtzman’s lab.) And another researcher, Tim Miller, MD, PhD, the Clayson Professor of Neurology, has made a discovery on ­antisense oligonucleotide treatment for tau, trying to prevent ­disease onset or halt disease progression, that will soon enter trials.

Further, researchers are making major new discoveries on what’s called the innate immune system, studying how cells in the brain — microglial cells — figure in modulating ­innate ­immunity, both to better understand Alzheimer’s and to develop treatments. “These cells can create, decrease or increase inflammatory ­reaction in the brain,” Holtzman says. “And we have some of the best people in the world working on this, trying to understand which molecules to modulate to turn the cells on or off.”

One molecule, called TREM2, was discovered about 15 years ago by Marco Colonna, MD, the Robert Rock Belleveau, MD, ­Professor of Pathology and Immunology. “We didn’t know then that it was ­connected with Alzheimer’s,” Holtzman says. “But four years ago, it was discovered that mutations in that gene put an ­individual at higher risk of getting the disease.” Since then, researchers in ­Colonna’s lab; Holtzman’s lab; the lab of Laura Piccio, MD, ­PhD, associate professor of neurology; and others have been trying to better understand TREM2’s role in the inflammatory response, ­trying to figure out whether to turn that on or off as a treatment.

In a recent study from Holtzman’s lab published in ­Nature, it was shown that the most important genetic risk factor for Alzheimer’s disease, APOE, appears to modulate brain ­injury in part through modulating the brain’s innate immune ­response. Holtzman says the big-picture issue is that ­inflammation is definitely involved in Alzheimer’s disease. Therefore, researchers are trying to determine how and when to alter that inflammatory response to best effect a change in progression at the individual level.

The next challenge: making progress

Looking toward the future on all these fronts, Dean Perlmutter says, “This is hard stuff and why Washington University needs to be at the forefront of what I call ‘the next huge challenge.’

“We’re in an era where medical researchers do sequencing, get big data, analyze it statistically, and then say, ‘OK, this is the gene that causes the disease.’ And many research centers will continue to do that,” Perlmutter says. “But our vision here is to take that ­sequence variant, put it into biological systems that are faithful and tractable models, and try, first, to understand whether the variant is truly ­causing the disease (exactly how and why) and, second, to use that knowledge to develop new diagnostics and therapeutics.”

Questions remain: How much effort will it take? And how much time? According to those on the front lines, it will take a massive effort and require lots of resources. And, as with any epic battle, it will require perseverance and incredible ­dedication and focus.

“But we’re making progress so much faster now than even 10 or five years ago, and that feels very different,” Skip Virgin says. “It feels as if we can run now, whereas before we were only crawling.”

Terri Nappier is editor of Washington magazine.

Comments and respectful dialogue are encouraged, but content will be moderated. Please, no personal attacks, obscenity or profanity, selling of commercial products, or endorsements of political candidates or positions. We reserve the right to remove any inappropriate comments.